| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ria Fisher, Atsuko Hikima, Rebecca Morris, Michael J Jackson, Sarah Rose, Mark A Varney, Ronan Depoortere, Adrian Newman-Tancred. The selective 5-HT Neuropharmacology. vol 167. 2021-04-23. PMID:32057799. |
the selective 5-ht l-dopa is the gold-standard pharmacotherapy for treatment of parkinson's disease (pd) but can lead to the appearance of troubling dyskinesia which are attributable to 'false neurotransmitter' release of dopamine by serotonergic neurons. |
2021-04-23 |
2023-08-13 |
Not clear |
| Kathryn Lanza, Christopher Bisho. Dopamine D3 Receptor Plasticity in Parkinson's Disease and L-DOPA-Induced Dyskinesia. Biomedicines. vol 9. issue 3. 2021-04-13. PMID:33808538. |
dopamine d3 receptor plasticity in parkinson's disease and l-dopa-induced dyskinesia. |
2021-04-13 |
2023-08-13 |
Not clear |
| Cong Zheng, Yan Xu, Guiqin Chen, Yang Tan, Weiqi Zeng, Ji Wang, Chi Cheng, Xiaoman Yang, Shuke Nie, Zhentao Zhang, Xuebing Ca. Distinct anti-dyskinetic effects of amantadine and group II metabotropic glutamate receptor agonist LY354740 in a rodent model: An electrophysiological perspective. Neurobiology of disease. vol 139. 2021-04-12. PMID:32088382. |
l-dopa-induced dyskinesia (lid) is a major complication of long-term dopamine replacement therapy in parkinson's disease. |
2021-04-12 |
2023-08-13 |
rat |
| Usha Gungabissoon, Oksana Kirichek, Céline El Baou, Nicholas Galwe. Comparison of long-term use of prolonged-release ropinirole and immediate-release dopamine agonists in an observational study in patients with Parkinson's disease. Pharmacoepidemiology and drug safety. vol 29. issue 5. 2021-04-08. PMID:32153056. |
to estimate the risk of dyskinesia and impulse control disorders (icds) in patients with parkinson's disease (pd) prescribed ropinirole prolonged-release (r-pr) compared to those prescribed immediate-release dopamine agonists (ir-da) as monotherapy. |
2021-04-08 |
2023-08-13 |
Not clear |
| Julia Castello, Marisol Cortés, Lauren Malave, Andreas Kottmann, David R Sibley, Eitan Friedman, Heike Rebhol. Publisher Correction: The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia. Scientific reports. vol 10. issue 1. 2021-03-13. PMID:32165689. |
publisher correction: the dopamine d5 receptor contributes to activation of cholinergic interneurons during l-dopa induced dyskinesia. |
2021-03-13 |
2023-08-13 |
Not clear |
| Sema Arisoy, Ozgun Sayiner, Tansel Comoglu, Deniz Onal, Ozbeyen Atalay, Bilge Pehlivanogl. Pharmaceutical development and technology. vol 25. issue 6. 2021-03-12. PMID:32141798. |
moreover, levodopa has psychic, gastrointestinal, and cardiovascular side effects, and most importantly, short and frequent stimulation of dopamine receptors lead to undesirable conditions such as dyskinesia over time. |
2021-03-12 |
2023-08-13 |
Not clear |
| Hyejin Park, Aarti N Urs, Joseph Zimmerman, Chuan Liu, Qiu Wang, Nikhil M Ur. Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands. ACS medicinal chemistry letters. vol 11. issue 3. 2021-03-12. PMID:32184974. |
the dopamine precursor l-dopa, the most commonly used therapeutic agent for parkinson's disease, can restore normal movement yet cause side-effects such as dyskinesias upon prolonged administration. |
2021-03-12 |
2023-08-13 |
Not clear |
| Louise-Laure Marian. Continuous and advanced treatment strategies in old and very old patients with Parkinson's disease. Geriatrie et psychologie neuropsychiatrie du vieillissement. 2021-03-09. PMID:33686944. |
on the other hand, patients presenting with advanced pd, in which fluctuations and dyskinesia induced by dopamine replacement therapy and dopa-resistant axial symptoms impede patient's daily life. |
2021-03-09 |
2023-08-13 |
Not clear |
| Rongfei Wang, Ming Sha. L-DOPA-elicited abnormal involuntary movements in the rats damaged severely in substantia nigra by 6-hydroxydopamine. Annals of palliative medicine. vol 9. issue 3. 2021-02-24. PMID:32279520. |
dyskinesia of rat models can occur in several conditions: acute levodopa (l-dopa) administration provided that the drug dose is sufficiently high and/or that the nigrostriatal dopamine (da) pathway is seriously damaged, and repeated l-dopa administration which could cause a reduction of the dyskinesia-threshold dose, a progressive aggravation and an increasing incidence of dyskinesia. |
2021-02-24 |
2023-08-13 |
rat |
| Andreas-Antonios Roussakis, Marta Gennaro, Nicholas P Lao-Kaim, David Towey, Paola Piccin. Dopamine Transporter Density in Journal of neuroinflammation and neurodegenerative diseases. vol 3. issue 1. 2021-01-10. PMID:31819926. |
dopamine transporter density in in parkinson's disease (pd), the onset of levodopa-induced dyskinesias (lids) is difficult to predict. |
2021-01-10 |
2023-08-13 |
Not clear |
| Chun-Lei Han, Yun-Peng Liu, Yun-Peng Sui, Ning Chen, Ting-Ting Du, Ying Jiang, Chen-Jia Guo, Kai-Liang Wang, Qiao Wang, Shi-Ying Fan, Michitomo Shimabukuro, Fan-Gang Meng, Fang Yuan, Jian-Guo Zhan. Integrated transcriptome expression profiling reveals a novel lncRNA associated with L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Aging. vol 12. issue 1. 2021-01-08. PMID:31929116. |
levodopa-induced dyskinesia (lid) is a common complication of chronic dopamine replacement therapy in the treatment of parkinson's disease (pd). |
2021-01-08 |
2023-08-13 |
rat |
| Erwan Bezard, Qin Li, Heather Hulme, Elva Fridjonsdottir, Anna Nilsson, Elsa Pioli, Per E Andren, Alan R Crossma. µ Opioid Receptor Agonism for L-DOPA-Induced Dyskinesia in Parkinson's Disease. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 40. issue 35. 2021-01-01. PMID:32690616. |
parkinson's disease (pd) is characterized by severe locomotor deficits and is commonly treated with the dopamine precursor l-dopa, but its prolonged usage causes dyskinesias referred to as l-dopa-induced dyskinesia (lid). |
2021-01-01 |
2023-08-13 |
Not clear |
| Keita Arakawa, Natsuko Yuge, Shunsuke Maehar. Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats. Pharmacological reports : PR. vol 72. issue 2. 2020-11-27. PMID:32144743. |
dopamine replacement therapy using l-3,4-dihydroxyphenylalanine (l-dopa) is a gold standard treatment in patients with parkinson's disease (pd); however, chronic administration of l-dopa causes excessive involuntary movements called l-dopa-induced dyskinesia. |
2020-11-27 |
2023-08-13 |
rat |
| Allan Lohse, David Meder, Silas Nielsen, Anders Elkjær Lund, Damian M Herz, Annemette Løkkegaard, Hartwig R Siebne. Low-frequency transcranial stimulation of pre-supplementary motor area alleviates levodopa-induced dyskinesia in Parkinson's disease: a randomized cross-over trial. Brain communications. vol 2. issue 2. 2020-11-24. PMID:33225277. |
levodopa-induced dyskinesia gradually emerges during long-term dopamine therapy, causing major disability in patients with parkinson disease. |
2020-11-24 |
2023-08-13 |
Not clear |
| Julia Castello, Marisol Cortés, Lauren Malave, Andreas Kottmann, David R Sibley, Eitan Friedman, Heike Rebhol. The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia. Scientific reports. vol 10. issue 1. 2020-11-12. PMID:32054879. |
the dopamine d5 receptor contributes to activation of cholinergic interneurons during l-dopa induced dyskinesia. |
2020-11-12 |
2023-08-13 |
Not clear |
| Fernando E Padovan-Neto, Santanna Patterson, Nivea M F Voelkner, Feras Altwal, Joel A Beverley, Anthony R West, Heinz Steine. Selective Regulation of 5-HT1B Serotonin Receptor Expression in the Striatum by Dopamine Depletion and Repeated L-DOPA Treatment: Relationship to L-DOPA-Induced Dyskinesias. Molecular neurobiology. vol 57. issue 2. 2020-11-05. PMID:31468338. |
selective regulation of 5-ht1b serotonin receptor expression in the striatum by dopamine depletion and repeated l-dopa treatment: relationship to l-dopa-induced dyskinesias. |
2020-11-05 |
2023-08-13 |
Not clear |
| Jing-Ya Lin, Zhen-Guo Liu, Cheng-Long Xie, Lu Song, Ai-Juan Ya. Antidyskinetic Treatment with MTEP Affects Multiple Molecular Pathways in the Parkinsonian Striatum. Parkinson's disease. vol 2017. 2020-10-01. PMID:29209553. |
standard treatment is still focused on the restoration of dopamine with exogenous l-dopa, which however causes l-dopa-induced dyskinesia (lid). |
2020-10-01 |
2023-08-13 |
rat |
| Rikinkumar S Patel, Saher Kamil, Mansi R Shah, Narmada Neerja Bhimanadham, Sundus Imra. Pros and Cons of Marijuana in Treatment of Parkinson's Disease. Cureus. vol 11. issue 6. 2020-10-01. PMID:31403009. |
current treatment options are scarce and include replacement of dopamine deficiency with levodopa which targets only motor symptoms of the disorder, does not halt its progression, and is associated with side effects of its own, including dyskinesia. |
2020-10-01 |
2023-08-13 |
Not clear |
| Masatoshi Ogawa, Yu Zhou, Ryosuke Tsuji, Jiro Kasahara, Satoshi Got. Intrastriatal Memantine Infusion Dampens Levodopa-Induced Dyskinesia and Motor Deficits in a Mouse Model of Hemiparkinsonism. Frontiers in neurology. vol 10. 2020-10-01. PMID:31866925. |
although the administration of dopamine precursor levodopa remains as the mainstay for the treatment of parkinson's disease, long-term exposure to levodopa often causes a disabling complication, referred to as levodopa-induced dyskinesias. |
2020-10-01 |
2023-08-13 |
mouse |
| Shashank Vasudevan, Janko Kajtez, Ada-Ioana Bunea, Ana Gonzalez-Ramos, Tania Ramos-Moreno, Arto Heiskanen, Merab Kokaia, Niels B Larsen, Alberto Martínez-Serrano, Stephan S Keller, Jenny Emnéu. Leaky Optoelectrical Fiber for Optogenetic Stimulation and Electrochemical Detection of Dopamine Exocytosis from Human Dopaminergic Neurons. Advanced science (Weinheim, Baden-Wurttemberg, Germany). vol 6. issue 24. 2020-10-01. PMID:31871869. |
however, the transplanted cells disperse in vivo and it is not possible to stimulate them on demand to modulate dopamine release to prevent dyskinesia. |
2020-10-01 |
2023-08-13 |
human |